Trial Profile

A Phase 1 study of MZE829 in healthy volunteer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MZE-829 (Primary)
Indications Renal failure
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

14 May 2025 According to Maze Therapeutics media release, company expects to report initial data, including proof-of-mechanism biomarker results, in the third quarter of 2025.
03 Dec 2024 According to Maze Therapeutics media release, today announced the completion of a $115 million Series D financing. This latest funding will support the advancement of company's lead programs, MZE829 and MZE782.
03 Dec 2024 According to Maze Therapeutics media release, data from the Phase 1 trial is expected in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com